Immunoglobulin News and Research RSS Feed - Immunoglobulin News and Research

Localised inflammation found in eosinophilic otitis media

Localised inflammation found in eosinophilic otitis media

Antigen-specific immunoglobulin E is produced locally in the middle ear mucosa of patients with eosinophilic otitis media, clinical research indicates. [More]
Inovio announces positive results on DNA-based monoclonal antibody therapy targeting CHIKV

Inovio announces positive results on DNA-based monoclonal antibody therapy targeting CHIKV

Inovio Pharmaceuticals, Inc. announced today that its novel DNA-based therapeutic monoclonal antibody targeting Chikungunya virus (CHIKV) completely protected mice from a lethal CHIKV challenge. [More]
Sanofi presents Phase II trial results for investigational vaccine for prevention of CDI

Sanofi presents Phase II trial results for investigational vaccine for prevention of CDI

Sanofi Pasteur, the vaccines division of Sanofi, presented Phase II (H-030-012) trial results for an investigational vaccine for the prevention of Clostridium difficile infection at the 114th General Meeting of the American Society for Microbiology. [More]
Shark antibodies reveal evolutionary principles of immunoglobulins

Shark antibodies reveal evolutionary principles of immunoglobulins

Custom-tailored antibodies are regarded as promising weapons against a multitude of serious illnesses. Since they can accurately recognize specific structures on the surface of viruses, bacteria or cancer cells, they are already being deployed successfully in cancer diagnostics and therapy, as well as against numerous other diseases. The stability of the sensitive antibodies is a decisive factor in every step, from production and storage to therapeutic application. [More]
Single-cell genomics study confirms that immune cells produce steroids

Single-cell genomics study confirms that immune cells produce steroids

Researchers at the European Bioinformatics Institute (EMBL-EBI) and the Wellcome Trust Sanger Institute have discovered that some immune cells turn themselves off by producing a steroid. [More]
Research provides fresh insight into structure of sodium channels

Research provides fresh insight into structure of sodium channels

Sodium channels are implicated in many serious conditions such as heart disease, epilepsy and pain, making them an important potential target for drug therapies. Unfortunately, there is still much scientists do not know about the molecules. [More]
Biogen Idec's ALPROLIX receives FDA approval for hemophilia B treatment

Biogen Idec's ALPROLIX receives FDA approval for hemophilia B treatment

Today Biogen Idec announced that the U.S. Food and Drug Administration has approved ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], the first recombinant, DNA derived hemophilia B therapy with prolonged circulation in the body. [More]
Biogen Idec's ALPROLIX gets Health Canada approval for hemophilia B

Biogen Idec's ALPROLIX gets Health Canada approval for hemophilia B

Today Biogen Idec announced that Health Canada has approved ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], for the control and prevention of bleeding episodes and routine prophylaxis in adults, and children aged 12 and older, with hemophilia B. [More]
Researchers look at health threat to pregnant women with history of Kawasaki disease

Researchers look at health threat to pregnant women with history of Kawasaki disease

In the first study of its type, researchers at the University of California, San Diego School of Medicine have looked at the health threat to pregnant women with a history of Kawasaki disease (KD), concluding that the risks are low with informed management and care. [More]
Protein M: an interview with Rajesh Grover, PhD, senior staff scientist, Lerner laboratory, TSRI

Protein M: an interview with Rajesh Grover, PhD, senior staff scientist, Lerner laboratory, TSRI

Protein M is a cell surface protein from Mycoplasma Genitalium that binds to all human antibodies. [More]
Infliximab drug shows promising results in treating children with Kawasaki Disease

Infliximab drug shows promising results in treating children with Kawasaki Disease

Kawasaki Disease (KD) is a severe childhood disease that many parents, even some doctors, mistake for an inconsequential viral infection. If not diagnosed or treated in time, it can lead to irreversible heart damage. [More]
Octapharma enrolls first patients in GAM-27 Phase II/III clinical trial for relapsing multiple sclerosis

Octapharma enrolls first patients in GAM-27 Phase II/III clinical trial for relapsing multiple sclerosis

Octapharma AG, one of the largest global manufacturers of human proteins, today announced the enrolment of the first two patients in its GAM-27 Phase II/III clinical trial for the treatment of relapsing multiple sclerosis. Through intravenous administration of immunoglobulin (Octagam 5%), the study seeks to support the overall clinical benefit of a lower annualised relapse rate in patients where first-line treatment is not suitable. [More]
Marker for inflammatory bowel disease linked to bipolar disorder

Marker for inflammatory bowel disease linked to bipolar disorder

Researchers have found evidence that the gastrointestinal tract plays a role in the inflammatory pathology of bipolar disorder, suggesting the need to consider dietary modification and anti-inflammatory treatment for some patients. [More]
Emergent BioSolutions enters into definitive agreement to acquire Cangene

Emergent BioSolutions enters into definitive agreement to acquire Cangene

Emergent BioSolutions Inc.announced that it has entered into a definitive agreement with Cangene Corporation (TSX: CNJ) under which Emergent will acquire all of the outstanding common shares of Cangene in an all-cash transaction valued at $3.24 per share on a fully diluted basis for an aggregate purchase price of $222 million. [More]
Scientists discover how lymphotoxin controls production of immunoglobulins in gut

Scientists discover how lymphotoxin controls production of immunoglobulins in gut

Lymphotoxin is a cytokine, or intercellular messenger, and plays an important role in the immunological balance of the gastrointestinal tract. It regulates the immune system of the digestive tract, which is made up of immune cells, immunoglobulins (antibodies) as well as intestinal bacteria. [More]
Autumn-born children prone to asthma

Autumn-born children prone to asthma

Month of birth closely correlates with the prevalence of bronchial asthma, a major study of Taiwanese children has found. [More]
EMA expands administration options for Hizentra

EMA expands administration options for Hizentra

CSL Behring UK Ltd announced today that the European Medicines Agency (EMA) has expanded the administration options for Hizentra®▼, human normal immunoglobulin, SCIg, 20% liquid, to include dosing once every two weeks (fortnightly). [More]
New evidence-based guidelines for diagnosis and assessment of atopic dermatitis

New evidence-based guidelines for diagnosis and assessment of atopic dermatitis

The American Academy of Dermatology (Academy) has released new evidence-based guidelines for the diagnosis and assessment of atopic dermatitis based on an extensive review of the scientific literature on this chronic skin condition characterized by itchy red patches of skin. [More]
Enrollment opens for IMO-8400 Phase 1/2 trial in patients with Waldenström's macroglobulinemia

Enrollment opens for IMO-8400 Phase 1/2 trial in patients with Waldenström's macroglobulinemia

Idera Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced that enrollment is open for a Phase 1/2 clinical trial of IMO-8400 in patients with Waldenström's macroglobulinemia, following acceptance of its Investigational New Drug application by the U.S. Food and Drug Administration. [More]
Biotest, EpiVax partner to develop novel, non-immunogenic Factor VIII for hemophilia treatment

Biotest, EpiVax partner to develop novel, non-immunogenic Factor VIII for hemophilia treatment

Biotest AG, Dreieich, Germany and EpiVax, Inc., Providence, Rhode Island, USA are pleased to announce a new Collaborative Research Agreement. With this collaboration a novel, non-immunogenic Factor VIII should be developed. [More]